Why did Lantheus’ FDA clearance for Tauklarify matter before the Curium deal?

Lantheus won FDA clearance for Tauklarify, an Alzheimer’s PET imaging agent, while awaiting its agreed $8 billion takeover by Curium. The approval strengthens Lantheus’ radiopharma portfolio at a sensitive deal stage and gives Curium another cleared imaging asset in a high-interest Alzheimer’s market.